Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425421 | 0.83 | DUT (0.53) | DUTP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL3759571 | 0.78 | POLB (0.55) | P2RY2P2RY6P2RY4 | |
| Phosphoric Acid SCHEMBL7906605 | 0.76 | DUT (0.55) | DUTP2RY2P2RY6P2RY4 | |
| SCHEMBL475343 | 0.76 | DUT (0.52) | DUTP2RY2P2RY6P2RY4 | |
| Deoxyuridine Monophosphate SCHEMBL25024676 | 0.75 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL888328 | 0.75 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL8200 | 0.75 | DUT (0.77) | DUTTYMS | |
| Deoxyuridine Monophosphate SCHEMBL21941035 | 0.75 | DUT (0.77) | DUTTYMS | |
| SCHEMBL5051998 | 0.75 | DUT (0.76) | DUTP2RY2P2RY6P2RY4TYMS | |
| Deoxyuridine SCHEMBL20585969 | 0.74 | DUT (0.64) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8388966-B2 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20090004200-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20060140962-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1372717-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030091574-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002076499-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |